Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials

• Participants must be greater than or equal to (\>=) 40 to less than or equal to (\<=) 80 years of age, at the time of signing the informed consent

• Elevated blood eosinophil count (BEC).

• Moderate to severe COPD with frequent exacerbations, defined as:

‣ A clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year

⁃ A post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio of less than (\<) 0.70 and a post- bronchodilator FEV1 \>30 percent (%) and \<= 80% predicted normal values

⁃ A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening

• COPD assessment test (CAT) score \>=10 at Visit 1

• Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years.

• Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1

• Body mass index (BMI) \>=16 kilogram per square meter (kg/m\^2).

• Male or eligible female participants